Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1/2 2Phase 3 1

Status

Completed 2

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Recurrence 1Neoplasms, Squamous Cell 1Neoplasm Metastasis 1Gliosarcoma 1Glioblastoma 1

Interventions

Cyclophosphamide 143pembrolizumab 126Nivolumab 114Carboplatin 99Dexamethasone 93Rituximab 91Paclitaxel 87Gemcitabine 85Lenalidomide 75Cytarabine 74Radiotherapy 72Cisplatin 70Bevacizumab 64Etoposide 62fludarabine phosphate 58fludarabine 56Docetaxel 54Bortezomib 54Ipilimumab 53Prednisone 49Doxorubicin 48Temozolomide 47Everolimus 46Erlotinib Hydrochloride 46Fluorouracil 44Azacitidine 44Capecitabine 43Calcium Dobesilate 43Filgrastim 42Melphalan 41

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Has results × Cilengitide × Clear all
NCT00085254 2016-02-25

Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

National Cancer Institute (NCI)

Phase 1/2 Completed
112 enrolled 14 charts
CNSSarcoma

Glioblastoma, Gliosarcoma

NCT00705016 2014-04-30

ADVANTAGE

Merck KGaA, Darmstadt, Germany

Phase 1/2 Completed
184 enrolled 20 charts

Neoplasm Metastasis, Recurrence, Neoplasms, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡